What did our AI researcher identify regarding "insulet nasdaqpodd issues fy 2026 earnings guidance"?

Insulet guided FY2026 EPS of $6.210 vs consensus $6.330.

What other signal did our AI researcher identify regarding "insulet nasdaqpodd issues fy 2026 earnings guidance"? (2)

Revenue guidance maintained at $3.3 billion.

What other signal did our AI researcher identify regarding "insulet nasdaqpodd issues fy 2026 earnings guidance"? (3)

Stock opened at $167.53, down 2.3%.

What other signal did our AI researcher identify regarding "insulet nasdaqpodd issues fy 2026 earnings guidance"? (4)

Q1 EPS $1.42 beat $1.19 estimate; revenue $761.7M beat $729.89M.

What other signal did our AI researcher identify regarding "insulet nasdaqpodd issues fy 2026 earnings guidance"? (5)

18 analysts rate Buy; consensus target $327.24.

dailypolitical.com

www.dailypolitical.com · May 6, 2026

Positive

insulet nasdaqpodd issues fy 2026 earnings guidance

TAX_FNCACT_ANALYSTSWB_698_TRADEWB_1331_HEALTH_TECHNOLOGIESWB_621_HEALTH_NUTRITION_AND_POPULATION

All News Read the full story on dailypolitical.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Insulet (PODD) is a medical device company focused on insulin pumps. The FY2026 EPS guidance miss (2% below consensus) signals potential margin pressure or higher costs, but revenue guidance unchanged. The commercial mechanism is a company-specific earnings revision; no broader sector or supply chain impact. Impact is single-company/supply-chain-specific.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

Insulet guided FY2026 EPS of $6.210 vs consensus $6.330.
Revenue guidance maintained at $3.3 billion.
Stock opened at $167.53, down 2.3%.
Q1 EPS $1.42 beat $1.19 estimate; revenue $761.7M beat $729.89M.
18 analysts rate Buy; consensus target $327.24.